📰 Kronos Bio News
Page 7 - Kronos Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kronos Bio. Real-time updates on events, politics, business and more.
January 30, 2023
/PRNewswire/ -- DelveInsights Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and...
December 11, 2022
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML ...
November 9, 2022
Item 2.02 Results of Operations and Financial Condition. On November 8, 2022, Kronos Bio, Inc. issued a press release providing a corporate update and announcing its financial results for the... | November 9, 2022
October 28, 2022
Angela Koehler, an associate professor of biological engineering at MIT, has made it her mission to find ways to drug “undruggable” targets. By taking aim at proteins that interact with these targets, she can indirectly disable them or reduce their impact.
October 3, 2022
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires - read this article along with other careers information, tips and advice on BioSpace
September 30, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...
September 29, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 -- RAPT Therapeutics, Inc. , a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral... | September 28, 2022
September 6, 2022
06.09.2022 - SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) - Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the ...
September 1, 2022
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for...
August 17, 2022
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 SAN MATEO, Calif. and SAN DIEGO, Aug. 17, 2022 /PRNewswire/ -- Kronos Bio, Inc....